Bharat Biotech's Covaxin effective against Delta plus variant, says study
Bharat Biotech's Covaxin
is effective against the Delta and Delta plus variant, a study by the Indian
Council of Medical Research and National Institute of Virology has said.
The study released on Monday showed that
Covaxin provides 65.2 per cent protection against the Delta variant which was
first detected in India. The Delta variant which has spread to 99 countries is
a variant of concern and was also responsible for the second wave in India.
The Delta variant has also been identified
as the leading cause of breakthrough infections globally among vaccinated
individuals, the study said. The study said that a minor reduction in the
neutralising antibody titer in Covid-19 recovered cases and full BBV152
vaccinated and post immunized infected cases was observed but the vaccine was
found to be effective against the Delta, Delta AY.1 and B.1.617.3 variants.
The study published as a pre-print on
bioRxiv said that Sera of vaccines among Covid naïve recovered cases with full
vaccination and breakthrough cases demonstrated 1.3, 2.5 and 1.9-fold reduction
against Delta variant in comparison to B.1 variant respectively. Read
More
Comments
Post a Comment